Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer of the visceral or parietal pleura, with greater than 90% of cases occurring in the setting of asbestos exposure. It is a relatively rare cancer, with an incidence of approximately 10 per 1 million person-years in the United States. It has a long latency period, up to 20 years after asbestos exposure, and the median age of diagnosis is 75 years old. [1,2]
Source: Lung Cancer - Category: Cancer & Oncology Authors: Andrew B. Thompson, Thomas J. Quinn, Zaid A. Siddiqui, Muayad F. Almahariq, Inga S. Grills, Craig W. Stevens Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Epidemiology | Lung Cancer | Mesothelioma | Study | USA Health